A Phase I/II Study of RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer.

Trial Profile

A Phase I/II Study of RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Apr 2017

At a glance

  • Drugs Everolimus (Primary) ; Tivozanib (Primary)
  • Indications Biliary cancer; Colorectal cancer; Gastric cancer; Liver cancer; Oesophageal cancer; Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 22 Jan 2016 Planned primary completion date changed from 1 Jun 2014 to 1 Jun 2016 as per ClinicalTrials.gov record.
    • 14 May 2013 Planned end date changed from 1 Oct 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 02 Mar 2012 Planned end date changed from 1 Oct 2011 to 1 Oct 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top